Newamsterdam Pharma Company N.V. (NAMS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 491,323 | 539,715 | 563,864 | 748,420 | 771,743 |
| Marketable Securities | 146,239 | 164,539 | 175,298 | 60,057 | 62,447 |
| Receivables | N/A | N/A | N/A | N/A | 4,951 |
| TOTAL | $675,700 | $732,328 | $769,850 | $817,304 | $863,413 |
| Non-Current Assets | |||||
| PPE Net | 383 | 323 | 312 | 238 | 242 |
| Investments And Advances | 92,609 | 53,091 | 44,172 | 0 | 0 |
| Intangibles | 407 | 439 | 470 | 502 | 534 |
| Other Non-Current Assets | 185 | 246 | 308 | 369 | 431 |
| TOTAL | $93,584 | $54,099 | $45,262 | $1,109 | $1,207 |
| Total Assets | $769,284 | $786,427 | $815,112 | $818,413 | $864,620 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 8,970 | 3,632 | 5,895 | 6,087 | 4,744 |
| Accrued Expenses | 15,422 | 10,098 | 9,460 | 8,021 | 13,608 |
| Other current liabilities | 57,272 | 44,361 | 20,932 | 23,523 | 82,312 |
| TOTAL | $85,787 | $58,272 | $36,512 | $40,913 | $106,918 |
| Non-Current Liabilities | |||||
| Deferred Revenues | 3,987 | N/A | N/A | 3,030 | 6,008 |
| Other Non-Current Liabilities | 66 | 85 | 103 | 137 | 202 |
| TOTAL | $66 | $85 | $103 | $137 | $202 |
| Total Liabilities | $85,853 | $58,357 | $36,615 | $41,050 | $107,120 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 114,975 | 113,391 | 112,629 | 112,271 | 109,818 |
| Common Shares | 14,278 | 14,107 | 14,014 | 13,968 | 13,444 |
| Retained earnings | -762,390 | -687,467 | -615,462 | -598,098 | -558,571 |
| Other shareholders' equity | 4,793 | 4,640 | 4,327 | 4,434 | 4,467 |
| TOTAL | $683,431 | $728,070 | $778,497 | $777,363 | $757,500 |
| Total Liabilities And Equity | $769,284 | $786,427 | $815,112 | $818,413 | $864,620 |